0001193125-26-089871
SEC filingTScan Therapeutics, Inc. reported financial results for Q4 and full year 2025, with revenue of $2.6 million in Q4 and $10.3 million for the year, R&D expenses of $20.0 million in Q4 and $114.2 million for the year, and net loss of $23.0 million in Q4 and $129.8 million for the year. Cash and cash equivalents stood at $152.4 million as of December 31, 2025, sufficient to fund operations into the second half of 2027.